Aquilo Capital Management, LLC
SAN FRANCISCO, CA · CIK 1591986 · 13F filing filed 2022-11-14
No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.
- Legal entityAQUILO CAPITAL MANAGEMENT, LLC (US)
- Others nearbySan Francisco, CA
$237.8m
reported value
14positions
92.1%in top 10
—no comparable previous quarter
Options: 0 call positions (— notional), 1 put positions ($39.7m notional) – listed below, not included above.
Holdings, Q3 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS IN ARWR | $40.3m16.94% | — |
| BLUEPRINT MEDICINES CORP BPMC | $34.5m14.53% | — |
| MERUS N V MRUS | $30.2m12.70% | — |
| ARVINAS INC ARVN | $29.9m12.57% | — |
| REGENXBIO INC RGNX | $25.6m10.76% | — |
| UNIQURE NV QURE | $15.8m6.64% | — |
| AMRYT PHARMA PLC SPONSORED ADS | $13.8m5.82% | — |
| SILENCE THERAPEUTICS PLC SLN | $12.7m5.33% | — |
| ARGENX SE ARGX | $8.5m3.56% | — |
| GENMAB A/S GMAB | $7.9m3.31% | — |
| KYMERA THERAPEUTICS INC KYMR | $7.2m3.02% | — |
| SPERO THERAPEUTICS INC SPRO | $6.8m2.86% | — |
| PIERIS PHARMACEUTICALS INC COM | $4.6m1.95% | — |
| 4D MOLECULAR THERAPEUTICS IN FDMT | $29.0k0.01% | — |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| SPDR SER TR XBI · Put | $39.7m500.0k shares | — |
Trades reported as a company insider in Q3 2022
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2022-09-22 | SPERO THERAPEUTICS INC 10% owner · See Footnotes | Sold | $4.3m1.9m shares |